Amarin Corp. ADR buy melinda
Summary
This prediction ended on 05.10.18 with a price of €17.30. The prediction had a final performance of 12.43%. melinda has 50% into this predictionAmarin Corporation plc (Symbol AMRN) is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to improve cardiovascular health. The company's main product, Vascepa, is a prescription medication that has been approved by the US FDA for use as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Vascepa has also shown to reduce the risk of cardiovascular events such as heart attack and stroke in patients with elevated cardiovascular risk. As a listed company, Amarin is publicly traded on the NASDAQ stock exchange and has a market capitalization of approximately $5 billion as of August 2021.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Amarin Corp. ADR | -0.588% | -0.588% | -28.992% | -77.346% |
iShares Core DAX® | 0.051% | 5.593% | 14.403% | 19.767% |
iShares Nasdaq 100 | 1.808% | 7.445% | 34.917% | 57.237% |
iShares Nikkei 225® | 2.181% | 2.815% | 11.116% | 8.873% |
iShares S&P 500 | 1.040% | 4.975% | 27.631% | 48.786% |
Comments by melinda for this prediction
In the thread Amarin Corp. ADR diskutieren
SecteurRecherche biotechnologique et médicale
Amarin Corporation plc, AMRN, a annoncé des résultats positifs dans l'essai REDUCE-IT sur les effets cardiovasculaires sur le vasocépa, qui est passé de l'huile de poisson. La FDA a publié une déclaration claire réaffirmant le profil avantages-risques de l'ACAD Nuplazid d'ACADIA Pharmaceuticals Inc. pour les patients atteints de psychose liée à la maladie de Parkinson.